A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer
Tekijät: Valta MP, Zhao HJ, Saar M, Tuomela J, Nolley R, Linxweiler J, Sandholm J, Lehtimaki J, Harkonen P, Coleman I, Nelson PS, Corey E, Peehl DM
Kustantaja: SPRINGER
Julkaisuvuosi: 2016
Journal: Clinical and Experimental Metastasis
Tietokannassa oleva lehden nimi: CLINICAL & EXPERIMENTAL METASTASIS
Lehden akronyymi: CLIN EXP METASTAS
Vuosikerta: 33
Numero: 4
Aloitussivu: 325
Lopetussivu: 337
Sivujen määrä: 13
ISSN: 0262-0898
eISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-016-9781-2
LuCaP serially transplantable patient-derived xenografts (PDXs) are valuable preclinical models of locally advanced or metastatic prostate cancer. Using spheroid culture methodology, we recently established cell lines from several LuCaP PDXs. Here, we characterized in depth the features of xenografts derived from LuCaP 136 spheroid cultures and found faithful retention of the phenotype of the original PDX. In vitro culture enabled luciferase transfection into LuCaP 136 spheroids, facilitating in vivo imaging. We showed that LuCaP 136 spheroids formed intratibial, orthotopic, and subcutaneous tumors when re-introduced into mice. Intratibial tumors responded to castration and were highly osteosclerotic. LuCaP 136 is a realistic in vitro-in vivo preclinical model of a subtype of bone metastatic prostate cancer.